ESMO2023 Opdivo/Nivo-related Oral Abstract Titles | BMY Message Board Posts


Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 
BOARD

GROUPS
 










Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message board, top of board
Msg  11707 of 12069  at  9/20/2023 11:44:23 AM  by

JBWIN


ESMO2023 Opdivo/Nivo-related Oral Abstract Titles

Proffered Paper session

1019O - Clinical and translational data from the Phase 1 SURPASS trial of ADP-A2M4CD8 T-cell receptor (TCR) T-cell therapy alone or combined with nivolumab in solid tumors

Presentation Number
1019O
Speakers
  • Victor Moreno Garcia (Madrid, Spain)
Lecture Time
11:08 - 11:18
Room
Burgos Auditorium - Hall 3
Date
Mon, 23.10.2023
Time
10:15 - 11:45
    Mini Oral session

    1513MO - A Phase II study of Nivolumab plus low dose Ipilimumab as 1st line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)

    Presentation Number
    1513MO
    Speakers
    • Kei Muro (Nagoya, Japan)
    Lecture Time
    17:15 - 17:20
    Room
    Bilbao Auditorium - NCC
    Date
    Sat, 21.10.2023
    Time
    16:30 - 18:00
      Mini Oral session

      855MO - Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): phase 2 trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1).

      Presentation Number
      855MO
      Speakers
      • Caroline Even (Villejuif, Cedex, France)
      Lecture Time
      10:15 - 10:20
      Room
      Málaga Auditorium - Hall 10
      Date
      Sat, 21.10.2023
      Time
      10:15 - 11:45
        Mini Oral session

        1021MO - Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors

        Presentation Number
        1021MO
        Speakers
        • Meredith Mckean (Nashville, United States of America)
        Lecture Time
        16:35 - 16:40
        Room
        Málaga Auditorium - Hall 10
        Date
        Sat, 21.10.2023
        Time
        16:30 - 18:00
          Mini Oral session

          1084MO - Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial

          Presentation Number
          1084MO
          Speakers
          • Anna M. Di Giacomo (Siena, Italy)
          Lecture Time
          14:50 - 14:55
          Room
          León Auditorium - Hall 7
          Date
          Sat, 21.10.2023
          Time
          14:45 - 16:15
            Proffered Paper session

            1082O - Concurrent Intrathecal (IT) and Intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD)

            Presentation Number
            1082O
            Speakers
            • Isabella C. Glitza (Houston, United States of America)
            Lecture Time
            09:20 - 09:30
            Room
            Valencia Auditorium - Hall 10
            Date
            Mon, 23.10.2023
            Time
            08:30 - 10:00
              Proffered Paper session

              724O - EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP); EOADR1-19/SPENCER

              Presentation Number
              724O
              Speakers
              • Eric Baudin (Villejuif, France)
              Lecture Time
              09:30 - 09:40
              Room
              Toledo Auditorium - Hall 3
              Date
              Sun, 22.10.2023
              Time
              08:30 - 10:00
                Proffered Paper session

                1261O - Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase 3 CheckMate 816 trial

                Presentation Number
                1261O
                Speakers
                • Mark M. Awad (Boston, United States of America)
                Lecture Time
                08:30 - 08:40
                Room
                Sevilla Auditorium - Hall 9
                Date
                Sun, 22.10.2023
                Time
                08:30 - 10:00
                  Mini Oral session

                  1083MO - Brain metastases and survival evaluation in the SECOMBIT trial

                  Presentation Number
                  1083MO
                  Speakers
                  • Paolo A. Ascierto (Napoli, Italy)
                  Lecture Time
                  14:45 - 14:50
                  Room
                  León Auditorium - Hall 7
                  Date
                  Sat, 21.10.2023
                  Time
                  14:45 - 16:15
                    Mini Oral session

                    2033MO - The impact of proton pump inhibitor (PPI) exposure before immune checkpoint inhibitor (ICI) therapy on overall survival (OS): A population-based study

                    Presentation Number
                    2033MO
                    Speakers
                    • Lawson Eng (Toronto, Canada)
                    Lecture Time
                    14:55 - 15:00
                    Room
                    Toledo Auditorium - Hall 3
                    Date
                    Sat, 21.10.2023
                    Time
                    14:45 - 16:15
                      Mini Oral session

                      657MO - Recommended phase 2 dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors

                      Presentation Number
                      657MO
                      Speakers
                      • Bob T. Li (New York, United States of America)
                      Lecture Time
                      16:35 - 16:40
                      Room
                      Valencia Auditorium - Hall 10
                      Date
                      Mon, 23.10.2023
                      Time
                      16:30 - 18:00


                             e-mail to a friend      printer-friendly     add to library      
                        |  
                        		Recs: 5  
                           Views: 0 []
                        Previous Message  Next Message    Post Message    Post a Reply return to message board, top of board




                        Financial Market Data provided by
                        .
                        Loading...